Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial

INTRODUCTION: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superio...

Descripción completa

Detalles Bibliográficos
Autores principales: Merle, Philippe, Kudo, Masatoshi, Edeline, Julien, Bouattour, Mohamed, Cheng, Ann-Lii, Chan, Stephen L., Yau, Thomas, Garrido, Marcelo, Knox, Jennifer, Daniele, Bruno, Breder, Valeriy, Lim, Ho Yeong, Ogasawara, Sadahisa, Cattan, Stéphane, Chao, Yee, Siegel, Abby B., Martinez-Forero, Iván, Wei, Ziwen, Liu, Chih-Chin, Finn, Richard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601873/
https://www.ncbi.nlm.nih.gov/pubmed/37901200
http://dx.doi.org/10.1159/000529636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601873/
https://www.ncbi.nlm.nih.gov/pubmed/37901200
http://dx.doi.org/10.1159/000529636

Ejemplares similares